NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Thursday that its fourth quarter revenues increased 60 percent year over year or 21 percent on an organic basis.

For the three months ended Dec. 31, the South San Francisco, Calif.-based firm reported total revenues of $33.5 million compared to $20.9 million in the year-ago period, just edging out its preannouncement of $33.4 million in revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.